Shaperon Inc.
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Inflammation
Shaperon is a clinical-stage biotechnology company headquartered in Seoul, South Korea, developing therapies for immune and inflammatory diseases with high unmet need, across both small molecules and next-generation biologics.
Shaperon's core pipeline is built around novel small-molecule GPCR19 positive allosteric modulators (PAMs). By selectively engaging a distinct allosteric site, the programs avoid the safety issues seen with prior orthosteric approaches and enable dual-phase regulation of the inflammasome, suppressing both priming and activation. Clinical programs span atopic dermatitis, diabetic foot ulcers, idiopathic pulmonary fibrosis, and Alzheimer's disease.
In parallel, Shaperon's proprietary NanoMab platform generates alpaca-derived single-domain antibodies in roughly three months and supports multi-specific formats, providing the foundation for the company's expansion into oncology and antiviral biologics.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2008
Lead Product in Development:
NuGel for atopic dermatitis
CEO
Seung-Yong (S.Y.) Seong
Development Phase of Lead Product
Phase II
Exchange
KOSDAQ
Ticker
378800
When you expect your next catalyst update?
September 2026
What is your next catalyst (value inflection) update?
Topline data for NuGel US Phase 2b studies expected in June; full clinical study report (CSR) completion expected September 2026.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}